{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T20:30:57Z","timestamp":1792614657624,"version":"4.5.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:00:00Z","timestamp":1764806400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019378","name":"Concert Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019378","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013671","name":"Sun Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013671","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.jaad.2025.11.070","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:48:16Z","timestamp":1764290896000},"page":"1134-1143","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1\/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 Phase 3, randomized, double-blind, controlled trial"],"prefix":"10.1016","volume":"94","author":[{"given":"Athanasios","family":"Tsianakas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Passeron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Magnolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Blume-Peytavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaiah","family":"Day","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocco","family":"Serrao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Guttman-Yassky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Sticherling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adri\u00e1na Evelin","family":"Csernus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar M.","family":"Moreno-Arrones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen","family":"Hamilton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Cassella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jaad.2025.11.070_bib1","first-page":"59","article-title":"Alopecia areata - current understanding and management","volume":"20","author":"Lintzeri","year":"2022","journal-title":"J Dtsch Dermatol Ges"},{"issue":"3","key":"10.1016\/j.jaad.2025.11.070_bib2","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jaad.2006.05.008","article-title":"Alopecia areata: a long term follow-up study of 191 patients","volume":"55","author":"Tosti","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2025.11.070_bib3","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.c3671","article-title":"Management of alopecia areata","volume":"341","author":"Harries","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.jaad.2025.11.070_bib4","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2147\/CCID.S245649","article-title":"A large cross-sectional survey study of the prevalence of alopecia areata in the United States","volume":"13","author":"Benigno","year":"2020","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2025.11.070_bib5","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1001\/jamadermatol.2023.0002","article-title":"Trends in prevalence and incidence of alopecia areata, alopecia totalis, and alopecia universalis among adults and children in a US employer-sponsored insured population","volume":"159","author":"Mostaghimi","year":"2023","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2025.11.070_bib6","first-page":"397","article-title":"Epidemiology and burden of alopecia areata: a systematic review","volume":"8","author":"Villasante Fricke","year":"2015","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"12","key":"10.1016\/j.jaad.2025.11.070_bib7","doi-asserted-by":"crossref","first-page":"2951","DOI":"10.1007\/s13555-023-01044-5","article-title":"Treatments for moderate-to-severe alopecia areata: a systematic narrative review","volume":"13","author":"Egeberg","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"12","key":"10.1016\/j.jaad.2025.11.070_bib8","doi-asserted-by":"crossref","first-page":"5504","DOI":"10.1007\/s12325-022-02338-4","article-title":"Treatment patterns and treatment satisfaction among adults with alopecia areata in the United States","volume":"39","author":"Fridman","year":"2022","journal-title":"Adv Ther"},{"issue":"1","key":"10.1016\/j.jaad.2025.11.070_bib9","first-page":"19","article-title":"JAK-inhibitors in dermatology - small molecules, big impact? Overview of the mechanism of action, previous study results and potential adverse effects","volume":"20","author":"Klein","year":"2022","journal-title":"J Dtsch Dermatol Ges"},{"issue":"5","key":"10.1016\/j.jaad.2025.11.070_bib13","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.jaad.2024.06.097","article-title":"Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: results from the phase 3 randomized, controlled trial (THRIVE-AA1)","volume":"91","author":"King","year":"2024","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2025.11.070_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2025.05.1032","article-title":"Optimization of deuruxolitinib dosing in adult patients with alopecia areata: results from a randomized, parallel-group, multicenter, phase 2 trial","volume":"93","author":"King","year":"2025","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2025.11.070_bib15","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.jaad.2003.09.032","article-title":"Alopecia areata investigational assessment guidelines--part II. National alopecia areata foundation","volume":"51","author":"Olsen","year":"2004","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2025.11.070_bib16","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.jaad.2022.03.045","article-title":"Phase 2 randomized, dose-ranging trial of CTP-543, a selective Janus kinase inhibitor, in moderate-to-severe alopecia areata","volume":"87","author":"King","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2025.11.070_bib17","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1111\/bjd.18883","article-title":"The alopecia areata investigator global assessment scale: a measure for evaluating clinically meaningful success in clinical trials","volume":"183","author":"Wyrwich","year":"2020","journal-title":"Br J Dermatol"},{"issue":"18","key":"10.1016\/j.jaad.2025.11.070_bib18","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1056\/NEJMoa2110343","article-title":"Two phase 3 trials of baricitinib for alopecia areata","volume":"386","author":"King","year":"2022","journal-title":"N Engl J Med"},{"issue":"10387","key":"10.1016\/j.jaad.2025.11.070_bib19","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/S0140-6736(23)00222-2","article-title":"Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial","volume":"401","author":"King","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2025.11.070_bib20","series-title":"Oral presentation at: American Academy of Dermatology Annual Meeting","article-title":"Deuruxolitinib demonstrates significant and continual improvement in scalp hair regrowth at 68 weeks of dosing in patients with alopecia areata: pooled efficacy results from ongoing open-label extensions of the THRIVE-AA1 and THRIVE-AA2 trials","author":"King","year":"2024"},{"issue":"10","key":"10.1016\/j.jaad.2025.11.070_bib21","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1001\/jamadermatol.2024.2734","article-title":"Baricitinib withdrawal and retreatment in patients with severe alopecia areata: the BRAVE-AA1 randomized clinical trial","volume":"160","author":"King","year":"2024","journal-title":"JAMA Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2025.11.070_bib22","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.jaad.2021.12.008","article-title":"Maintenance, withdrawal, and re-treatment with ritlecitinib and brepocitinib in patients with alopecia areata in a single-blind extension of a phase 2a randomized clinical trial","volume":"87","author":"Peeva","year":"2022","journal-title":"J Am Acad Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962225032839?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962225032839?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T08:25:55Z","timestamp":1791879955000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962225032839"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0190962225032839"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2025.11.070","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1\/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 Phase 3, randomized, double-blind, controlled trial","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2025.11.070","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}